Financial reports
ARS
2023 FY
Annual report to shareholders
29 Mar 24
10-K
2023 FY
Annual report
27 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
3 Apr 23
10-K
2022 FY
Annual report
23 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
Current reports
8-K
Entry into a Material Definitive Agreement
29 Mar 24
8-K
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
27 Mar 24
8-K
Other Events
5 Dec 23
8-K
Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
13 Nov 23
8-K
Celcuity Inc. Announces $50 Million Private Placement
23 Oct 23
8-K
Departure of Directors or Certain Officers
23 Aug 23
8-K
Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer
22 Aug 23
8-K
Celcuity Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
10 Aug 23
8-K
Celcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updates
15 May 23
8-K
Departure of Directors or Certain Officers
12 May 23
Registration and prospectus
D/A
$75.38 mm in debt / options / securities to be acquired, sold $35.00 mm, 1 investor
25 Apr 24
424B3
Prospectus supplement
29 Nov 23
D/A
$2.98 mm in securities to be acquired, sold $2.60 mm, 38 investors
27 Nov 23
D/A
$6.61 mm in securities to be acquired, sold $5.93 mm, 39 investors
27 Nov 23
S-3/A
Shelf registration (amended)
22 Nov 23
S-3
Shelf registration
14 Nov 23
D
$50.00 mm in options / securities to be acquired, sold $50.00 mm, 2 investors
26 Oct 23
S-8
Registration of securities for employees
16 May 23
D/A
$75.38 mm in debt / options / securities to be acquired, sold $35.00 mm, 1 investor
2 May 23
S-8
Registration of securities for employees
2 Mar 23
Proxies
DEFA14A
Additional proxy soliciting materials
28 Mar 24
DEF 14A
Definitive proxy
28 Mar 24
DEF 14A
Definitive proxy
31 Mar 23
DEFA14A
Additional proxy soliciting materials
31 Mar 23
DEFA14A
Additional proxy soliciting materials
19 Jul 22
DEF 14A
Definitive proxy
19 Jul 22
PRE 14A
Preliminary proxy
7 Jul 22
DEF 14A
Definitive proxy
11 Apr 22
PRE 14A
Preliminary proxy
30 Mar 22
DEFA14A
Additional proxy soliciting materials
31 Mar 21
Other
EFFECT
Notice of effectiveness
29 Nov 23
CORRESP
Correspondence with SEC
24 Nov 23
UPLOAD
Letter from SEC
21 Nov 23
EFFECT
Notice of effectiveness
13 Jan 23
CORRESP
Correspondence with SEC
9 Jan 23
UPLOAD
Letter from SEC
5 Jan 23
EFFECT
Notice of effectiveness
29 Nov 21
CORRESP
Correspondence with SEC
23 Nov 21
UPLOAD
Letter from SEC
22 Nov 21
EFFECT
Notice of effectiveness
6 Apr 21
Ownership
4
Richard E Buller
26 Apr 24
144
Notice of proposed sale of securities
24 Apr 24
4
Richard E Buller
10 Apr 24
4
Brian F. Sullivan
20 Mar 24
4
Richard E Buller
23 Feb 24
4
Vicky Hahne
15 Feb 24
4
Lance G. Laing
15 Feb 24
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24